Ülke: Singapur
Dil: İngilizce
Kaynak: HSA (Health Sciences Authority)
Perindopril tert-butylamine
SERVIER (S) PTE LTD
C09AA04
8 mg
TABLET
Perindopril tert-butylamine 8 mg
ORAL
Prescription Only
Les Laboratoires Servier Industrie
ACTIVE
2004-12-23
1. NAME OF THE MEDICINAL PRODUCT Coversyl 4 mg Coversyl 8 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 4 mg perindopril tert-butylamine salt, equivalent to 3.338 mg of perindopril 8 mg perindopril tert-butylamine salt, equivalent to 6.676 mg perindopril Excipients: Microcrystalline cellulose, lactose monohydrate, Hydrophobic colloidal silica, magnesium stearate, aluminium copper complexes of chlorophyllins (E141 ii) lake 3. PHARMACEUTICAL FORM Coversyl 4 mg: Tablets, light green, oblong, engraved with on one face and scored on both edges. Coversyl 8 mg Tablets: Tablets, green, round, biconvex, engraved with on one face and on the other. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Hypertension Treatment of hypertension Heart Failure Treatment of symptomatic heart failure Stable coronary artery disease: Reduction of risk of cardiac events in patients with a history of myocardial infarction and/or revascularisation. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION It is recommended that COVERSYL is taken once daily in the morning before a meal. The dose should be individualised according to the patient profile (see 4.4 “Special warnings and special precautions for use”) and blood pressure response. Hypertension COVERSYL may be used in monotherapy or in combination with other classes of antihypertensive therapy. The recommended starting dose is 4 mg given once daily in the morning. Patients with a strongly activated renin-angiotensin-aldosterone system (in particular, renovascular hypertension, salt and/or volume depletion, cardiac decompensation or severe hypertension) may experience an excessive drop in blood pressure following the initial dose. A starting dose of 2 mg is recommended in such patients and the initiation of treatment should take place under medical supervision. The dose may be increased to 8 mg once daily after one month of treatment. Symptomatic hypotension may occur following initiation of therapy with COVERSYL; this is more likely in patients who are b Belgenin tamamını okuyun
1. NAME OF THE MEDICINAL PRODUCT Coversyl 4 mg Coversyl 8 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 4 mg perindopril tert-butylamine salt, equivalent to 3.338 mg of perindopril 8 mg perindopril tert-butylamine salt, equivalent to 6.676 mg perindopril Excipients: Microcrystalline cellulose, lactose monohydrate, Hydrophobic colloidal silica, magnesium stearate, aluminium copper complexes of chlorophyllins (E141 ii) lake 3. PHARMACEUTICAL FORM Coversyl 4 mg: Tablets, light green, oblong, engraved with on one face and scored on both edges. Coversyl 8 mg Tablets: Tablets, green, round, biconvex, engraved with on one face and on the other. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Hypertension Treatment of hypertension Heart Failure Treatment of symptomatic heart failure Stable coronary artery disease: Reduction of risk of cardiac events in patients with a history of myocardial infarction and/or revascularisation. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION It is recommended that COVERSYL is taken once daily in the morning before a meal. The dose should be individualised according to the patient profile (see 4.4 “Special warnings and special precautions for use”) and blood pressure response. Hypertension COVERSYL may be used in monotherapy or in combination with other classes of antihypertensive therapy. The recommended starting dose is 4 mg given once daily in the morning. Patients with a strongly activated renin-angiotensin-aldosterone system (in particular, renovascular hypertension, salt and/or volume depletion, cardiac decompensation or severe hypertension) may experience an excessive drop in blood pressure following the initial dose. A starting dose of 2 mg is recommended in such patients and the initiation of treatment should take place under medical supervision. The dose may be increased to 8 mg once daily after one month of treatment. Symptomatic hypotension may occur following initiation of therapy with COVERSYL; this is more likely in patients who are being treated concur- rently wit Belgenin tamamını okuyun